Pacira BioSciences (PCRX) Change in Receivables (2010 - 2026)

Pacira BioSciences' Change in Receivables history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 118.31% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $20.9 million, a 571.86% increase from a year earlier, with the FY2025 full-year figure at $10.7 million, up 38.64% from the prior year.
• Change in Receivables slipped to $1.6 million in Q1 2026 per PCRX's latest filing, from $8.8 million in the prior quarter.
• Across five years, Change in Receivables topped out at $12.7 million in Q4 2024 and bottomed at -$8.6 million in Q1 2025.
• The 5-year median for Change in Receivables is $1.6 million (2026), against an average of $1.7 million.
• Across the five-year window, Change in Receivables tumbled 812.34% in 2022 and surged 688.68% in 2023, its largest moves.
• Year by year, Change in Receivables stood at $4.9 million in 2022, then jumped by 74.56% to $8.6 million in 2023, then soared by 47.12% to $12.7 million in 2024, then tumbled by 30.45% to $8.8 million in 2025, then plunged by 82.19% to $1.6 million in 2026.
• Per Business Quant, the three latest PCRX Change in Receivables figures stand at $1.6 million (Q1 2026), $8.8 million (Q4 2025), and $897000.0 (Q3 2025).